Iproteos, from protein-protein interactions to peptide drugs

The company focuses its activity on the Research and Development and Innovation of new therapeutic strategies based on modulation of protein-ligand (PLI) and protein-protein interactions (PPIs) through non-natural peptides or peptidomimetics obtained thanks to the IPRO technology. Specifically, at Iproteos we are specialized on diseases of the central nervous system (CNS), where a deregulation of a PPI could be restored to normal levels through the action of a peptide ligand. PPIs are emergent therapeutic targets, since their dysfunction has been observed in a wide range of diseases.

    Partners        IPRO_technology        diseases